Evidence map›Paper›PMID 40296839›Full record

ArticleJournal of microbiology and biotechnology2025

Investigation of a Natural Antibiotic's Properties Effective against Resistant Opportunistic Pathogenic Infections.

Almagul Khassenova, Yerik Shorabayev, Sirina Zhantlessova, Baiken Baimakhanova, Aisha Sultanova, Makpal Yelubaeva

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of microbiology and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Almagul KhassenovaIndustrial Microbiology LLP, Almaty 050040, Kazakhstan.
Yerik ShorabayevIndustrial Microbiology LLP, Almaty 050040, Kazakhstan.
Sirina ZhantlessovaAl-Farabi Kazakh National University, Almaty 050040, Kazakhstan.
Baiken BaimakhanovaResearch and Production Center for Microbiology and Virology LLP, Almaty 050010, Kazakhstan.
Aisha SultanovaIndustrial Microbiology LLP, Almaty 050040, Kazakhstan.
Makpal YelubaevaResearch and Production Center for Microbiology and Virology LLP, Almaty 050010, Kazakhstan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The widespread use of antibiotics has led to several negative consequences, including the development of multidrug resistance in microorganisms to previously effective medications. Antibiotic resistance is an increasingly critical issue in both inpatient and outpatient settings. The problem is complicated by the decline in the development of innovative drugs to combat the most dangerous and resistant pathogens. One approach to addressing this challenge is to search for producers of new natural compounds with antibiotic activity. The primary objective of this study was to identify streptomycetes capable of synthesizing complex antibiotics with antibacterial properties. In this study, actinomycetes were isolated from the arid soils in Kazakhstan, followed by the analysis of their antagonistic properties. The greatest interest was generated by isolate No. 312, obtained from rocky soils of the Almaty region and grown on oat agar. The article describes the biochemical, cultural-taxonomic, and antagonistic properties of the new actinomycete. The new antibiotic exhibited the strongest antagonistic activity against clinical strains of

Indexed as

ActinobacteriaAnti-Bacterial AgentsStreptomycesAntibiosisDrug Resistance, Multiple, BacterialEscherichia coliHumansKazakhstanMethicillin-Resistant Staphylococcus aureusMicrobial Sensitivity TestsSoil MicrobiologyStaphylococcus aureusAnti-Bacterial AgentsActinomycetesantibacterial propertiesantibioticsopportunistic pathogenic bacteriaspectrum of activity

Identifiers

PMID40296839
PMCPMC12089949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.